Merrill T, et al. Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE). CR 2018, abstract L14.
Upadacitinib laat gunstige effecten zien bij RA-patiëntgroepen
aug 2018 | RA